. . "Pagoclone"@en . "133737-32-3"@en . . . . . . . . . . . . . . . . . . . . . . "Pagoclone is a subtype-selective drug which binds primarily to the alpha2/alpha3 subtypes of the GABAA receptor which are responsible for the anti-anxiety effects of these kind of drugs, but has relatively little efficacy at the alpha1 subtype which produces the sedative and memory loss effects."@en . "For the potential treatment of panic and anxiety disorders."@en . . . . "Pagoclone is an anxiolytic drug from the cyclopyrrolone family, which is related to other more well known drugs such as the sleeping medication zopiclone. It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures."@en . "# de Wit H, Vicini L, Haig GM, Hunt T, Feltner D: Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. J Clin Psychopharmacol. 2006 Jun;26(3):268-73. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16702891 # Atack JR, Pike A, Marshall G, Stanley J, Lincoln R, Cook SM, Lewis RT, Blackaby WP, Goodacre SC, McKernan RM, Dawson GR, Wafford KA, Reynolds DS: The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagoclone. Neuropharmacology. 2006 May;50(6):677-89. Epub 2006 Jan 20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16430927 # Bateson A: Pagoclone Indevus. Curr Opin Investig Drugs. 2003 Jan;4(1):91-5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12625036 # Sandford JJ, Forshall S, Bell C, Argyropoulos S, Rich A, D'Orlando KJ, Gammans RE, Nutt DJ: Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. J Psychopharmacol. 2001 Sep;15(3):205-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11565630"@en . . . "investigational"@en . . . . . . " "@en . "Humans and other mammals"@en .